Predicting Dexamethasone-Associated Extubation Success in Preterm Infants

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Dexamethasone is used to improve respiratory status in preterm infants with lung disease.
• Dexamethasone affects heart rate variability, influencing the heart rate characteristics index (HRCi), a sepsis risk score.
• Respiratory improvement is often measured by the ability to reduce ventilatory support, quantified by the respiratory severity score (RSS).

Purpose of the Study:

• To investigate the association between early dexamethasone treatment, HRCi, and RSS with respiratory improvement, specifically successful extubation.
• To determine if HRCi and RSS predict successful extubation in preterm infants receiving dexamethasone for lung disease.

Main Methods:

• Retrospective review of 65 preterm infants (gestational age < 32 weeks) receiving >3 days of dexamethasone for lung disease.
• Analysis of daily FiO2, HRCi, and RSS for the start day of dexamethasone and the 2 days before and after.
• Comparison of variables between infants who were successfully extubated (no reintubation within 7 days) and those who were not.

Main Results:

• Dexamethasone treatment led to significant decreases in HRCi, FiO2, and RSS by day 3.
• Successful extubation (n=38) was associated with higher postmenstrual age (PMA), lower FiO2 and RSS, and conventional ventilation.
• Multivariable analysis identified RSS and PMA as predictors of successful extubation, while HRCi did not predict success.

Conclusions:

• While dexamethasone improved HRCi in preterm infants with lung disease, this improvement did not correlate with extubation success.
• Higher PMA and lower respiratory support (RSS) were key factors associated with successful extubation during dexamethasone therapy.
• Fifty-eight percent of infants achieved successful extubation during dexamethasone treatment, highlighting the importance of PMA and RSS.